WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$6.20 USD
-0.04 (-0.64%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $6.19 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
WAVE Life Sciences Ltd. [WVE]
Reports for Purchase
Showing records 41 - 57 ( 57 total )
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Muscular Dystrophy BD Teams Might Want to Take Notice of the New Kid on the Block
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Certitude on Data Timing Should Alleviate Pressure on the Stock
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
DYSTANCE 51 Underway; Speed of Enrollment Predicated Upon OLE Study Biopsy Data Prior to YE19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
A Show Me Story With Company/Platform Defining Events During 4Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Systemic Therapy of DMD With Stereopure PS-ASO''s Remains Uncertain; Removing From Our Model and Lowering Target to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
2019 Is the Year When the Rubber Meets the Road: Model Updates Post Recent Financing
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Limited Clarity From the Positive Safety Findings; Awaiting Formal Presentation at a Scientific Venue
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
3Q18 Corporate Update; Clinically, Not Much New to Write Home About
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
A Few More Months to the First-in-Human Data With Stereopure ASO
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Stereopure Oligos: A Road Less Traveled; Assuming Coverage With a Buy and $49 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-120101 and WVE-120102 Enter the Clinic for Huntington''s Disease; New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
IND Filings for WVE-120101 and WVE-120102 to Treat Huntington''s Disease (HD)Expected Mid-2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
We are initiating with a Buy rating and a $41 12-month price target
Provider: H.C. Wainwright & Co., Inc.